Kalıtsal Metabolik Hastalıklarda Ketojenik Diyet
Özet
Kalıtsal metabolizma hastalıkları (KMH), biyokimyasal yolaklarda görev alan proteinlerin sentez veya işlev bozukluğu sonucu ortaya çıkan genetik hastalıklardır ve geleneksel diyet tedavisi bu hastalıkların yönetiminde temel yaklaşımı oluşturmaktadır. Yüksek lipid, düşük karbonhidrat ve yeterli protein oranına sahip olan ketojenik diyet (KD), katabolizma oluşturmaksızın ketozis sağlayarak açlık metabolizmasına benzer bir biyokimyasal ortam meydana getirmektedir. KMH yönetiminde KD iki ana işleve sahiptir: kusurlu biyokimyasal basamağı atlayarak hücresel enerji metabolizmasının devamlılığını sağlamak ve dirençli epilepsi, kas güçsüzlüğü ile motor gelişim geriliği gibi klinik bulguları kontrol altına almaktır. KD özellikle kan-beyin bariyerindeki glukoz taşıma kusurunu monokarboksilik asit taşıyıcıları üzerinden bypass eden GLUT1 eksikliği sendromunda ve alternatif asetil-CoA kaynağı sunarak enerji üretimini destekleyen Piruvat Dehidrogenaz (PDH) kompleks eksikliğinde ilk seçenek temel tedavi yöntemidir. Bunun yanı sıra Adenilosuksinat Liyaz (ADSL) eksikliği, Glikojen Depo Hastalıkları (Tip 3, Tip 5), Lafora hastalığı ve İzole Kompleks I eksikliği gibi mitokondriyal hastalıklarda da KD'nin nöbet sıklığını belirgin şekilde azalttığı, kardiyak fonksiyonları ve egzersiz kapasitesini iyileştirdiği gösterilmiştir. Ancak metabolik dekompansasyon riskini engellemek amacıyla KMH hastalarında KD uygulaması açlık ve katabolizmadan kaçınılarak titiz bir klinik ve biyokimyasal takip altında sürdürülmelidir.
Referanslar
Scriver CR. Garrod’s croonian lectures (1908) and the charter “inborn errors of metabolism”: Albinism, alkaptonuria, cystinuria, and pentosuria at age 100 in 2008. J Inherit Metab Dis. 2008;31: 580–98.
Ferreira CR, van Karnebeek CDM, Vockley J, Blau N. A proposed nosology of inborn errors of metabolism. Genet Med. 2019; 21: 102–106.
Gambello MJ, Li H. Current strategies for the treatment of inborn errors of metabolism. J Genet and Genom. 2018;45: 61–70.
Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia open. 2018;3:175–92.
Ye F, Li XJ, Jiang WL, Sun H Bin, Liu J. Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: A meta-analysis. J Clin Neurol. 2015;11:26–31.
Hallböök T, Sjölander A, Åmark P, Miranda M, Bjurulf B, Dahlin M. Effectiveness of the ketogenic diet used to treat resistant childhood epilepsy in Scandinavia. Eur J Paediatr Neurol. 2015;19:29–36.
Scholl-Bürgi S, Höller A, Pichler K, Michel M, Haberlandt E, Karall D. Ketogenic diets in patients with inherited metabolic disorders. J Inherit Metab Dis. 2015;38:765–73.
Jurecka A, Opoka-Winiarska V, Rokicki D, Tylki-Szymałska A. Neurologic presentation, diagnostics, and therapeutic insights in a severe case of adenylosuccinate lyase deficiency. J Child Neurol. 2012;27:645-9.
Jurecka A, Zikanova M, Jurkiewicz E, Tylki-Szymańska A. Attenuated adenylosuccinate lyase deficiency: A report of one case and a review of the literature. Neuropediatrics. 2014;45:50-5.
Cusmai R, Martinelli D, Moavero R, et al. Ketogenic diet in early myoclonic encephalopathy due to non ketotic hyperglycinemia. Eur J Paediatr Neurol. 2012;16:509-13.
kava MP, Robertson A, Greed L, Balasubramaniam S. Ketogenic diet, a potentially valuable therapeutic option for the management of refractory epilepsy in classical neonatal nonketotic hyperglycinemia: a case report. Eur J Clin Nutr. 2019;73:961-965.
Nylen K, Velazquez JLP, Likhodii SS, et al. A ketogenic diet rescues the murine succinic semialdehyde dehydrogenase deficient phenotype. Exp Neurol. 2008;210:449-57.
Nylen K, Velazquez JLP, Sayed V, Gibson KM, Burnham WM, Snead OC. The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1-/- mice. Biochim Biophys Acta - Gen Subj. 2009;1790:208-12.
Peuscher R, Dijsselhof ME, Abeling NG, Van Rijn M, Van Spronsen FJ, Bosch AM. The ketogenic diet is well tolerated and can be effective in patients with argininosuccinate lyase deficiency and refractory epilepsy. JIMD Reports. 2012;5:127-30.
Klepper J, Akman C, Armeno M, et al. Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open.2020;5:354–65.
Kass HR, Winesett SP, Bessone SK, Turner Z, Kossoff EH. Use of dietary therapies amongst patients with GLUT1 deficiency syndrome. Seizure. 2016; 35:83-87.
Israelian L, Wang P, Gabrielian S, Zhao X, Minassian BA. Ketogenic diet reduces Lafora bodies in murine Lafora disease. Neurol Genet. 2020;6:e533.
Cardinali S, Canafoglia L, Bertoli S, et al. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res. 2006;69:129–34.
Tarnopolsky MA, Nilsson MI. Nutrition and exercise in Pompe disease. Ann Transl Med. 2019; 7:282.
Olgac A, İnci A, Okur İ, et al. Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa. Ann Nutr Metab. 2020; 76:233-241.
Brambilla A, Mannarino S, Pretese R, Gasperini S, Galimberti C, Parini R. Improvement of cardiomyopathy after high-fat diet in two siblings with glycogen storage disease type iii. JIMD Reports. 2014; 17:91-5.
Valayannopoulos V, Bajolle F, Arnoux JB, et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with d,l-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res. 2011; 70:638-41.
Løkken N, Hansen KK, Storgaard JH, Ørngreen MC, Quinlivan R, Vissing J. Titrating a modified ketogenic diet for patients with McArdle disease: A pilot study. J Inherit Metab Dis. 2020;43:778-786.
Busch V, Gempel K, Hack A, et al. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol. 2005; 58:341.
Similä ME, Auranen M, Piirilä PL. Beneficial Effects of Ketogenic Diet on Phosphofructokinase Deficiency (Glycogen Storage Disease Type VII). Front Neurol. 2020;11:57.
Falk RE, Cederbaum SD, Blass JP, Gibson GE, Kark RA, Carrel RE. Ketonic diet in the management of pyruvate dehydrogenase deficiency. Pediatrics. 1976;58:713-21
Sofou K, Dahlin M, Hallböök T, Lindefeldt M, Viggedal G, Darin N. Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis. 2017;40:237-245.
Martikainen MH, Päivärinta M, Jääskeläinen S, Majamaa K. Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet. Epileptic Disord. 2012;14:438-441.
Cardenas JF, Amato RS. Compound heterozygous polymerase gamma gene mutation in a patient with alpers disease. Semin Pediatr Neurol. 2010;17:62-64.
Steriade C, Andrade DM, Faghfoury H, Tarnopolsky MA, Tai P. Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) may respond to adjunctive ketogenic diet. Pediatr Neurol. 2014;50:498-502.
Villamizar-Schiller IT, Pabón LA, Hufnagel SB, Serrano NC, Karl G, Jefferies JL, et al. Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease. Eur J Med Genet. 2015;58:180-3.
Joshi C, Kolbe DL, Mansilla MA, Mason S, Smith RJH, Campbell CA. Ketogenic diet – A novel treatment for early epileptic encephalopathy due to PIGA deficiency. Brain Dev. 2016;38:848-51.
Paketci C, Edem P, Hiz S, et al. Successful treatment of intractable epilepsy with ketogenic diet therapy in twins with ALG3-CDG. Brain Dev. 2020;42:539-45.
Barba C, Darra F, Cusmai R, et al. Congenital disorders of glycosylation presenting as epileptic encephalopathy with migrating partial seizures in infancy. Dev Med Child Neurol. 2016;58:1085–91.
Yates TM, Suri M, Desurkar A, et al. SLC35A2-related congenital disorder of glycosylation: Defining the phenotype. Eur J Paediatr Neurol. 2018;22:1095–102.
Ng BG, Eklund EA, Shiryaev SA, et al. Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatment suggestions. J Inherit Metab Dis. 2020;43:1333–48.
Castro M, Carrillo R, García F, et al. Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism. Nucleosides, Nucleotides and Nucleic Acids. 2014;33:223–40.
Jurecka A, Zikanova M, Kmoch S, Tylki-Szymańska A. Adenylosuccinate lyase deficiency. Journal of Inherited Metabolic Disease. 2015;38:231-42.
Pong AW, Geary BR, Engelstad KM, Natarajan A, Yang H, De Vivo DC. Glucose transporter type i deficiency syndrome: Epilepsy phenotypes and outcomes. Epilepsia. 2012;53:1503–10.
Pearson TS, Pons R, Engelstad K, Kane SA, Goldberg ME, De Vivo DC. Paroxysmal eye-head movements in Glut1 deficiency syndrome. Neurology. 2017;88:1666–73.
Suls A, Dedeken P, Goffin K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain. 2008;131:1831–44.
Leen WG, Wevers RA, Kamsteeg EJ, Scheffer H, Verbeek MM, Willemsen MA. Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: A systematic review. JAMA Neurology. 2013;70:1440–4.
Wang D, Pascual JM, Yang H, et al. Glut-1 deficiency syndrome: Clinical, genetic, and therapeutic aspects. Ann Neurol. 2005; 57:111–8.
Pascual JM, Liu P, Mao D, et al. Triheptanoin for Glucose Transporter Type I Deficiency (G1D): Modulation of Human Ictogenesis, Cerebral Metabolic Rate, and Cognitive Indices by a Food Supplement. JAMA Neurol . 2014;71:1255–65.
Brewer MK, Putaux JL, Rondon A, Uittenbogaard A, Sullivan MA, Gentry MS. Polyglucosan body structure in Lafora disease. Carbohydr Polym. 2020;240:116260.
Bedoyan JK, Hage R, Shin HK, et al. Utility of specific amino acid ratios in screening for pyruvate dehydrogenase complex deficiencies and other mitochondrial disorders associated with congenital lactic acidosis and newborn screening prospects. JIMD Rep. 2020;56:70-81.
Shelkowitz E, Ficicioglu C, Stence N, Van Hove J, Larson A. Serial Magnetic Resonance Imaging (MRI) in Pyruvate Dehydrogenase Complex Deficiency. J Child Neurol. 2020;35:137-145.
Rahman S. Mitochondrial disease and epilepsy. Developmental Medicine and Child Neurology. 2012;54:397-406.
Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia. 2007;48:82-88.